Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Interaction of Opicapone and Levodopa/Benserazide
NCT02169895Phase 1Completed
- Sponsor
- BIAL
- Start
- Sep 2008
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of opicapone in Parkinson's disease (PD) (4 arms), sponsored by BIAL. Primary endpoints: Maximum Observed Plasma Drug Concentration at 72 hours, Time of Occurrence of Cmax at 72 hours and 1 more. Started Sep 2008; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02169895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02169895.